VHL ligand 1 (TFA) is widely used in targeted protein degradation research, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a key component to bind the von Hippel-Lindau (VHL) E3 ubiquitin ligase, facilitating the degradation of specific proteins of interest. This compound is instrumental in studying disease mechanisms, especially in cancer, where it helps degrade oncogenic proteins. It is also utilized in chemical biology to explore protein function and validate drug targets. Additionally, VHL ligand 1 (TFA) plays a role in designing novel therapeutic strategies by enabling selective protein knockdown in cellular and preclinical models.